{"id":"W4399481376","doi":"10.1136/annrheumdis-2024-eular.250","title":"POS0527 DEUCRAVACITINIB, A FIRST-IN-CLASS, ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): EFFICACY BY BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN THE PHASE 2 PAISLEY TRIAL","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Demographics; Systemic lupus erythematosus; Internal medicine; Pharmacology; Disease; Oncology; Demography","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007964396,0.0003502968,0.0007348089,0.0004179487,0.00009487929,0.0001187705,0.0002477385,0.00007953776,0.00004269883],"category_scores_gemma":[0.002812132,0.0002221169,0.0002998537,0.001108319,0.0001798246,0.0001807371,0.00008535064,0.0003716469,0.000005100354],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004988323,"about_ca_system_score_gemma":0.0003093294,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001401306,"about_ca_topic_score_gemma":0.00007427543,"domain_scores_codex":[0.9971712,0.0004417429,0.001111131,0.0004233823,0.000459135,0.0003933931],"domain_scores_gemma":[0.9974872,0.001362683,0.0002562458,0.0005205014,0.000119542,0.0002537726],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1855998,0.08183985,0.289404,0.04246692,0.002461659,0.003736701,0.01500048,0.0003630811,0.01525467,0.003316764,0.2925,0.0680562],"study_design_scores_gemma":[0.3337915,0.01383926,0.1968585,0.2212043,0.00662961,0.003029923,0.006722348,0.1807188,0.004753551,0.005453328,0.02192228,0.005076563],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9830065,0.008986646,0.00003355566,0.004852223,0.0005365095,0.001727538,0.0007883665,0.00004895571,0.00001970774],"genre_scores_gemma":[0.9968116,0.002071673,0.00001316622,0.0005542284,0.00009226205,0.0001850524,0.0001828342,0.00004500879,0.00004423547],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2705777,"threshold_uncertainty_score":0.9057666,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03300773911830283,"score_gpt":0.3178285190322137,"score_spread":0.2848207799139108,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}